XOMA Corporation
$ 25.41
0.33%
26 Feb - close price
- Market Cap N/A
- Current Price $ 25.41
- High / Low $ 25.44 / 25.34
- Stock P/E 25.29
- Book Value 7.14
- EPS 1.00
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.22 %
- 52 Week High 25.46
- 52 Week Low 21.92
About
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and Asia Pacific. The company is headquartered in Emeryville, California.
Analyst Target Price
N/A
Quarterly Earnings
| Sep 2025 | Jun 2025 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-13 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
| Reported EPS | 0.7 | 0.44 | -0.5131 | -0.3128 | -0.7031 | 1.5248 | -0.1 | -0.3264 | -0.4875 | -0.3847 | 0.2024 | -0.4667 |
| Estimated EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise | 0.7 | 0.44 | -0.5131 | -0.3128 | -0.7031 | 1.5248 | -0.1 | -0.3264 | -0.4875 | -0.3847 | 0.2024 | -0.4667 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Feb 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Previous Dividend Records
| Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-01-15 | 2025-10-15 | 2025-07-15 | 2025-04-15 | 2025-01-15 | 2024-10-15 | 2024-07-15 | 2024-04-15 | 2024-01-16 | 2023-10-16 |
| Amount | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XOMAO
2026-02-17 06:52:00
This article analyzes Xoma Corporation (NASDAQ: XOMA) stock, highlighting a weak near and mid-term sentiment that could impact its long-term positive outlook. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with detailed multi-timeframe signal analysis for support and resistance levels. The analysis emphasizes the importance of these signals for tactical trading decisions.
2026-02-14 06:59:49
TD Cowen analyst Phil Nadeau has maintained a Hold rating on XOMA Corp (XOMA.US). According to TipRanks data, Nadeau has a 48.8% success rate and an average return of 7.4% over the past year. TipRanks provides analysis data from financial analysts, calculating average returns and success rates for informational purposes.
2026-02-11 01:29:04
This article discusses XOMAO, XOMA Royalty Corporation's 8.375% cumulative preferred stock, highlighting its compelling income potential despite call risk. The author believes its dividend durability is solid due to XOMA's healthy balance sheet and continued aggregation of royalty interests and corporate deals, including 24 new assets in 2025. The company's positioning to benefit from Section 174 tax attributes further enhances the attractiveness of XOMAO as an income vehicle with biotech exposure.
2026-02-10 11:28:16
This article analyzes XOMA Royalty Corporation's Return On Equity (ROE), which stands at 20%, comparing it to the Biotech industry average of 19%. While the ROE is acceptable, the analysis highlights that XOMA Royalty uses a high amount of debt (debt to equity ratio of 1.03), which can artificially boost ROE and introduce higher risk. Investors are advised to consider other factors like future profit growth and debt levels alongside ROE when evaluating the company.
2026-02-10 05:29:56
XOMA Royalty Corporation has completed its acquisition of Generation Bio Co. for $4.2913 per share in cash plus a contingent value right. The acquisition, which concluded after a tender offer, makes Generation Bio a wholly owned subsidiary of XOMA Royalty. This strategic move occurred despite Generation Bio's strong liquidity and market capitalization, with XOMA acquiring the company at a discount to its Fair Value according to InvestingPro data.
2026-02-09 14:29:45
XOMA Royalty Corporation has successfully completed its tender offer and acquisition of Generation Bio Co. Generation Bio stockholders received $4.2913 per share in cash plus a contingent value right. As a result, Generation Bio is now a wholly-owned subsidiary of XOMA Royalty and its shares have ceased trading on Nasdaq.
